Mesothelin as a biomarker for clinical management of esophageal adenocarcinoma
间皮素作为食管腺癌临床治疗的生物标志物
基本信息
- 批准号:8386226
- 负责人:
- 金额:$ 23.87万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2012
- 资助国家:美国
- 起止时间:2012-08-01 至 2014-07-31
- 项目状态:已结题
- 来源:
- 关键词:Adjuvant TherapyBiologicalBiological MarkersBloodBlood TestsCancer PatientCell surfaceCleaved cellClinicalClinical ManagementClinical TrialsCombined Modality TherapyDataDatabasesDifferentiation AntigensDiseaseEsophagealEsophageal AdenocarcinomaEvaluationExcisionImageImmunohistochemistryIncidenceIndividualInterventionLymph Node InvolvementMalignant neoplasm of ovaryMalignant neoplasm of pancreasMeasuresMemorial Sloan-Kettering Cancer CenterMesotheliomaModalityN-terminalOperative Surgical ProceduresOutcomePathological StagingPatientsPeptidesProtocols documentationPublicationsRadiation therapyRecording of previous eventsRecurrenceResearch InfrastructureResearch ProposalsResectedResistanceSamplingSerumStagingSurvival RateTestingTherapeuticTimeTissuesTumor BurdenValidationWidespread Diseaseadvanced diseasebasecancer cellcandidate selectiondesignhigh riskimprovedinstrumentmesothelinmigrationoutcome forecastpre-clinicalprospectiveresearch clinical testingresponsestandard of caretreatment responsetumor
项目摘要
DESCRIPTION (provided by applicant): A Prospective Clinical Trial to Evaluate Mesothelin as a Biomarker for the Clinical Management of Esophageal Adenocarcinoma (EAC) Patients The incidence of esophageal adenocarcinoma (EAC) is rising at an annual rate of 8%. Most EAC patients present at an advanced stage disease with an overall 5-year survival rate of 10%. Of the patients who present with potentially curable disease, majority will already have local-regional advanced disease. Although combined modality treatment, the current standard of care for locally advanced disease, improves survival, lack of accurate clinical evaluation of tumor burden and treatment response is a significant limitation in selecting appropriate treatment in a timely fashion. In spite of the radiographic and endoscopic imaging, one in four patients with a presumed early-stage disease are found to have more extensive disease (T3 or N1) at the time of surgery. These patients would have benefited from multimodality therapy. In patients treated with neo- adjuvant therapy for local-regional advanced disease, assessment of therapy response remains inaccurate. Identification and validation of a biomarker that reflects tumor burden, therapy response, and recurrence will be highly valuable for the clinical management and clinical trials of EAC patients. In this research proposal, based on our promising retrospective data, we aim to investigate serum and tissue mesothelin as a biomarker to improve the clinical management of EAC patients. Mesothelin is a cell surface tumor-differentiation antigen, the N-terminal of which is cleaved and secreted into blood, measured as serum soluble mesothelin-related peptide (SMRP). Increased SMRP levels are demonstrated in mesothelioma, pancreatic and ovarian cancer patients. Recent publications have demonstrated that the level of SMRP correlates with tumor load, therapy response, and prognosis in mesothelioma patients. We propose: Specific Aim 1: To prospectively evaluate whether serum SMRP levels correlate with (a) clinical staging, (b) response to neo-adjuvant therapy, and (c) disease recurrence in surgically resected EAC patients. Specific Aim 2: To prospectively investigate whether tissue mesothelin expression (a) pre chemo-radiation therapy is a predictor of poor therapy response, and (b) post-resection is a predictor of poor survival. The novelty and impact of this carefully designed prospective proposal extends beyond biomarker study in testing the utility of mesothelin as a marker of Barrett's transformation to EAC; it is immediately
translational to benefit 15,000 patients with EAC.
PUBLIC HEALTH RELEVANCE: A simple predictive instrument to identify early-stage esophageal adenocarcinoma patients at higher risk for poor therapy response and recurrence; therefore the most likely candidates for selection of therapeutic modality or aggressive surveillance will benefit. In this research proposal, based on our promising retrospective data, we aim to investigate serum and tissue mesothelin as a biomarker to improve the clinical management of esophageal adenocarcinoma patients.
描述(由申请人提供):评估间皮素作为食管腺癌 (EAC) 患者临床管理生物标志物的前瞻性临床试验食管腺癌 (EAC) 的发病率以每年 8% 的速度上升。大多数 EAC 患者已处于晚期疾病,总体 5 年生存率为 10%。在患有潜在可治愈疾病的患者中,大多数已经患有局部晚期疾病。尽管联合治疗(目前局部晚期疾病的护理标准)可以提高生存率,但缺乏对肿瘤负荷和治疗反应的准确临床评估是及时选择适当治疗的重大限制。尽管进行了放射照相和内窥镜成像,四分之一的假定患有早期疾病的患者在手术时发现患有更广泛的疾病(T3或N1)。这些患者将受益于多学科治疗。在接受新辅助治疗的局部晚期疾病的患者中,治疗反应的评估仍然不准确。反映肿瘤负荷、治疗反应和复发的生物标志物的鉴定和验证对于 EAC 患者的临床管理和临床试验非常有价值。 在这项研究计划中,基于我们有希望的回顾性数据,我们旨在研究血清和组织间皮素作为生物标志物,以改善 EAC 患者的临床管理。间皮素是一种细胞表面肿瘤分化抗原,其 N 末端被切割并分泌到血液中,以血清可溶性间皮素相关肽 (SMRP) 的形式进行测量。间皮瘤、胰腺癌和卵巢癌患者中 SMRP 水平升高。最近的出版物表明,SMRP 水平与间皮瘤患者的肿瘤负荷、治疗反应和预后相关。我们建议: 具体目标 1:前瞻性评估手术切除的 EAC 患者中血清 SMRP 水平是否与 (a) 临床分期、(b) 对新辅助治疗的反应和 (c) 疾病复发相关。具体目标 2:前瞻性研究组织间皮素表达是否 (a) 放化疗前是治疗反应不良的预测因素,(b) 切除后是不良生存的预测因素。这一精心设计的前瞻性提案的新颖性和影响力超出了生物标志物研究的范围,用于测试间皮素作为 Barrett 向 EAC 转化的标志物的效用;是立即
使 15,000 名 EAC 患者受益。
公共卫生相关性:一种简单的预测工具,可识别治疗反应不佳和复发风险较高的早期食管腺癌患者;因此,最有可能选择治疗方式或积极监测的候选人将会受益。在这项研究计划中,基于我们有希望的回顾性数据,我们旨在研究血清和组织间皮素作为生物标志物,以改善食管腺癌患者的临床管理。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Prasad S. Adusumilli其他文献
臨床病期I期の肺腺癌における組織亜型による経時的再発ハザードの層別化の有用性
根据临床 I 期肺腺癌的组织学亚型随时间推移对复发风险进行分层的实用性
- DOI:
- 发表时间:
2021 - 期刊:
- 影响因子:0
- 作者:
高橋 祐介;Prasad S. Adusumilli - 通讯作者:
Prasad S. Adusumilli
原核生物由来ナトリウムチャネルに創出された二価カチオ ンによる電流阻害の分子機構
原核钠通道中产生的二价阳离子抑制电流的分子机制
- DOI:
- 发表时间:
2023 - 期刊:
- 影响因子:0
- 作者:
高橋 祐介;Prasad S. Adusumilli;入江 克雅 - 通讯作者:
入江 克雅
Therapeutic effect of oncolytic herpes simplex virus (NV1066) on radioresistant head and neck squamous cell carcinoma
- DOI:
10.1016/j.jamcollsurg.2005.06.146 - 发表时间:
2005-09-01 - 期刊:
- 影响因子:
- 作者:
Se-Heon Kim;Richard J. Wong;David Eisenberg;Yun Shin Chun;Zhenkun Yu;Prasad S. Adusumilli;Jatin P. Shah;Yuman Fong - 通讯作者:
Yuman Fong
Commission on Cancer Standards for Lymph Node Sampling and Oncologic Outcomes After Lung Resection
癌症委员会关于肺切除术后淋巴结采样及肿瘤学预后的标准
- DOI:
10.1016/j.athoracsur.2024.09.009 - 发表时间:
2025-02-01 - 期刊:
- 影响因子:3.900
- 作者:
Benjamin J. Resio;Kay See Tan;Matthew Skovgard;Joe Dycoco;Prasad S. Adusumilli;Manjit S. Bains;Matthew J. Bott;Robert J. Downey;Katherine D. Gray;James Huang;Daniela Molena;Bernard J. Park;Valerie W. Rusch;Smita Sihag;Gaetano Rocco;David R. Jones;James M. Isbell - 通讯作者:
James M. Isbell
The Emerging Role of Immunotherapy in Resectable Non-Small Cell Lung Cancer
- DOI:
10.1016/j.athoracsur.2024.01.024 - 发表时间:
2024-07-01 - 期刊:
- 影响因子:
- 作者:
Elizabeth G. Dunne;Cameron N. Fick;James M. Isbell;Jamie E. Chaft;Nasser Altorki;Bernard J. Park;Jonathan Spicer;Patrick M. Forde;Daniel Gomez;Puneeth Iyengar;David H. Harpole;Thomas E. Stinchcombe;Moishe Liberman;Matthew J. Bott;Prasad S. Adusumilli;James Huang;Gaetano Rocco;David R. Jones - 通讯作者:
David R. Jones
Prasad S. Adusumilli的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Prasad S. Adusumilli', 18)}}的其他基金
A phase I/II combination immunotherapy clinical trial: mesothelin-targeted chimeric antigen receptor T cells and checkpoint blockade agent in pleural mesothelioma
I/II期联合免疫治疗临床试验:间皮素靶向嵌合抗原受体T细胞和检查点阻断剂治疗胸膜间皮瘤
- 批准号:
10208821 - 财政年份:2019
- 资助金额:
$ 23.87万 - 项目类别:
A phase I/II combination immunotherapy clinical trial: mesothelin-targeted chimeric antigen receptor T cells and checkpoint blockade agent in pleural mesothelioma
I/II期联合免疫治疗临床试验:间皮素靶向嵌合抗原受体T细胞和检查点阻断剂治疗胸膜间皮瘤
- 批准号:
10658882 - 财政年份:2019
- 资助金额:
$ 23.87万 - 项目类别:
A phase I/II combination immunotherapy clinical trial: mesothelin-targeted chimeric antigen receptor T cells and checkpoint blockade agent in pleural mesothelioma
I/II期联合免疫治疗临床试验:间皮素靶向嵌合抗原受体T细胞和检查点阻断剂治疗胸膜间皮瘤
- 批准号:
10445296 - 财政年份:2019
- 资助金额:
$ 23.87万 - 项目类别:
Image-guided irreversible electroporation directed CAR T-cell delivery to solid tumors
图像引导不可逆电穿孔引导 CAR T 细胞递送至实体瘤
- 批准号:
10221646 - 财政年份:2018
- 资助金额:
$ 23.87万 - 项目类别:
Image-guided irreversible electroporation directed CAR T-cell delivery to solid tumors
图像引导不可逆电穿孔引导 CAR T 细胞递送至实体瘤
- 批准号:
10478835 - 财政年份:2018
- 资助金额:
$ 23.87万 - 项目类别:
Image-guided irreversible electroporation directed CAR T-cell delivery to solid tumors
图像引导不可逆电穿孔引导 CAR T 细胞递送至实体瘤
- 批准号:
9764302 - 财政年份:2018
- 资助金额:
$ 23.87万 - 项目类别:
Imaging the efficacy of TRAIL-enhanced cancer immunotherapy
TRAIL 增强癌症免疫疗法的功效成像
- 批准号:
9387986 - 财政年份:2017
- 资助金额:
$ 23.87万 - 项目类别:
Mesothelin as a biomarker for clinical management of esophageal adenocarcinoma
间皮素作为食管腺癌临床治疗的生物标志物
- 批准号:
8508213 - 财政年份:2012
- 资助金额:
$ 23.87万 - 项目类别:
Validation of a risk model for stage I lung adenocarcinoma
I 期肺腺癌风险模型的验证
- 批准号:
8386244 - 财政年份:2012
- 资助金额:
$ 23.87万 - 项目类别:
Validation of a risk model for stage I lung adenocarcinoma
I 期肺腺癌风险模型的验证
- 批准号:
8508212 - 财政年份:2012
- 资助金额:
$ 23.87万 - 项目类别:
相似海外基金
MRI and Biological Markers of Acute E-Cigarette Exposure in Smokers and Vapers
吸烟者和电子烟使用者急性电子烟暴露的 MRI 和生物标志物
- 批准号:
10490338 - 财政年份:2021
- 资助金额:
$ 23.87万 - 项目类别:
MRI and Biological Markers of Acute E-Cigarette Exposure in Smokers and Vapers
吸烟者和电子烟使用者急性电子烟暴露的 MRI 和生物标志物
- 批准号:
10353104 - 财政年份:2021
- 资助金额:
$ 23.87万 - 项目类别:
Investigating pollution dynamics of swimming pool waters by means of chemical and biological markers
利用化学和生物标记物研究游泳池水体的污染动态
- 批准号:
21K04320 - 财政年份:2021
- 资助金额:
$ 23.87万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
MRI and Biological Markers of Acute E-Cigarette Exposure in Smokers and Vapers
吸烟者和电子烟使用者急性电子烟暴露的 MRI 和生物标志物
- 批准号:
10688286 - 财政年份:2021
- 资助金额:
$ 23.87万 - 项目类别:
Novel biological markers for immunotherapy and comprehensive genetic analysis in thymic carcinoma
用于胸腺癌免疫治疗和综合遗传分析的新型生物标志物
- 批准号:
20K17755 - 财政年份:2020
- 资助金额:
$ 23.87万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Examination of Biological Markers Associated with Neurobehavioral and Neuropsychological Outcomes in Military Veterans with a History of Traumatic Brain Injury
与有脑外伤史的退伍军人的神经行为和神经心理结果相关的生物标志物的检查
- 批准号:
10578649 - 财政年份:2019
- 资助金额:
$ 23.87万 - 项目类别:
Examination of Biological Markers Associated with Neurobehavioral and Neuropsychological Outcomes in Military Veterans with a History of Traumatic Brain Injury
与有脑外伤史的退伍军人的神经行为和神经心理结果相关的生物标志物的检查
- 批准号:
10295141 - 财政年份:2019
- 资助金额:
$ 23.87万 - 项目类别:
Examination of Biological Markers Associated with Neurobehavioral and Neuropsychological Outcomes in Military Veterans with a History of Traumatic Brain Injury
与有脑外伤史的退伍军人的神经行为和神经心理结果相关的生物标志物的检查
- 批准号:
10041708 - 财政年份:2019
- 资助金额:
$ 23.87万 - 项目类别:
Examination of Biological Markers Associated with Neurobehavioral and Neuropsychological Outcomes in Military Veterans with a History of Traumatic Brain Injury
与有脑外伤史的退伍军人的神经行为和神经心理结果相关的生物标志物的检查
- 批准号:
9776149 - 财政年份:2019
- 资助金额:
$ 23.87万 - 项目类别:
Combining biological and non-biological markers to develop a model predictive of treatment response for individuals with depression
结合生物和非生物标志物来开发预测抑郁症患者治疗反应的模型
- 批准号:
2063934 - 财政年份:2018
- 资助金额:
$ 23.87万 - 项目类别:
Studentship